{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:25:26Z","timestamp":1765369526698,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.canrad.2019.07.138","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T08:08:57Z","timestamp":1566893337000},"page":"773-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer du canal anal\u00a0: personnalisation de la dose, du volume et du fractionnement"],"prefix":"10.1016","volume":"23","author":[{"given":"D.","family":"Peiffert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.07.138_bib0005","doi-asserted-by":"crossref","first-page":"e018726","DOI":"10.1136\/bmjopen-2017-018726","article-title":"Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer","volume":"7","author":"Fish","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.canrad.2019.07.138_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2017.11.018","article-title":"Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer","volume":"126","author":"Sodergren","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF02555448","article-title":"Epidermoid carcinoma of the anal canal. A series of 276\u00a0cases","volume":"30","author":"Papillon","year":"1987","journal-title":"Diseases of the colon and rectum"},{"key":"10.1016\/j.canrad.2019.07.138_bib0020","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.07.138_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1748-717X-7-201","article-title":"Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?","volume":"7","author":"Dewas","year":"2012","journal-title":"Radiation oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0030","first-page":"39","article-title":"Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointestinal cancer research: GCR"},{"key":"10.1016\/j.canrad.2019.07.138_bib0035","doi-asserted-by":"crossref","first-page":"618","DOI":"10.21037\/jgo.2018.05.07","article-title":"Impact of intensity modulated radiation therapy on survival in anal cancer","volume":"9","author":"Jhaveri","year":"2018","journal-title":"Journal of gastrointestinal oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0040","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1002\/cncr.31721","article-title":"Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.07.138_bib0045","series-title":"The study has been presented in The European Cancer Congress","article-title":"Pooled analysis of external-beam radiotherapy parameters in phase II and phase III trials in radiochemotherapy in anal cancer (PARADAC)","author":"Rivin del Campo","year":"2013"},{"key":"10.1016\/j.canrad.2019.07.138_bib0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2018.10.021","article-title":"Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence","volume":"131","author":"Rouard","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2\u00a0evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"10.1016\/j.canrad.2019.07.138_bib0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Advances in radiation oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijrobp.2017.02.005","article-title":"Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529","volume":"98","author":"Olsen","year":"2017","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"10.1016\/j.canrad.2019.07.138_bib0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2018.05.044","article-title":"Intensity Modulated Radiation Therapy Versus Conventional Radiation for Anal Cancer in the Veterans Affairs System","volume":"102","author":"Bryant","year":"2018","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"10.1016\/j.canrad.2019.07.138_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/COC.0000000000000009","article-title":"Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study","volume":"39","author":"Call","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0080","first-page":"1943","article-title":"Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2019.07.138_bib0085","first-page":"2027","article-title":"Locally Advanced (T3-T4\u00a0or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2019.07.138_bib0090","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0095","doi-asserted-by":"crossref","first-page":"466","DOI":"10.21037\/jgo.2018.03.03","article-title":"Utilization of intensity modulated radiation therapy for anal cancer in the United States","volume":"9","author":"Haque","year":"2018","journal-title":"Journal of gastrointestinal oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0100","doi-asserted-by":"crossref","first-page":"20439","DOI":"10.18632\/oncotarget.24926","article-title":"The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy","volume":"9","author":"Hosni","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2019.07.138_bib0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12032-018-1197-1","article-title":"Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy","volume":"35","author":"Klausner","year":"2018","journal-title":"Medical oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2017.01.006","article-title":"The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma","volume":"98","author":"Pollom","year":"2017","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"10.1016\/j.canrad.2019.07.138_bib0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/0284186X.2015.1124141","article-title":"Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal","volume":"55","author":"Tomasoa","year":"2016","journal-title":"Acta oncologica"},{"key":"10.1016\/j.canrad.2019.07.138_bib0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clon.2015.08.006","article-title":"Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3\u00a0Year Outcomes at Two Sydney Institutions","volume":"27","author":"Yates","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2019.05.018","article-title":"Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)","volume":"140","author":"Vendrely","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5114\/jcb.2018.81025","article-title":"Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal","volume":"10","author":"Bertin","year":"2018","journal-title":"Journal of contemporary brachytherapy"},{"key":"10.1016\/j.canrad.2019.07.138_bib0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.canrad.2018.07.131","article-title":"[Anal canal cancer: In the era of intensity-modulated radiotherapy, outstanding issues]","volume":"22","author":"Peiffert","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.138_bib0140","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2018.08.008","article-title":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2\u00a0and ACCORD 03)","volume":"129","author":"Faivre","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0145","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"10.1016\/j.canrad.2019.07.138_bib0150","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0155","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.canrad.2018.07.012","article-title":"Traitement du cancer du canal anal: premiers r\u00e9sultats de la cohorte nationale Anabase","volume":"22","author":"Vendrely","year":"2018","journal-title":"Cancer Radioth\u00e9rapie"},{"key":"10.1016\/j.canrad.2019.07.138_bib0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.adro.2017.04.007","article-title":"Quantitative FDG-PET\/CT predicts local recurrence and survival for squamous cell carcinoma of the anus","volume":"2","author":"Cardenas","year":"2017","journal-title":"Advances in radiation oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0165","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.canrad.2018.06.019","article-title":"[Image-guided radiotherapy contribution and patient setup for anorectal cancer treatment]","volume":"22","author":"Masson","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.138_bib0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12885-019-5447-1","article-title":"HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report","volume":"19","author":"Harle","year":"2019","journal-title":"BMC cancer"},{"key":"10.1016\/j.canrad.2019.07.138_bib0180","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2019.07.138_bib0185","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16\u00a0phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0190","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0195","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","article-title":"Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer","volume":"51","author":"Leon","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2019.07.138_bib0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16\u00a0phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.138_bib0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2\u00a0study","volume":"18","author":"Morris","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.canrad.2019.07.138_bib0210","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1\u00a0antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:34:35Z","timestamp":1761136475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819303142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1278321819303142"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.138","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer du canal anal\u00a0: personnalisation de la dose, du volume et du fractionnement","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}